US › Healthcare

Passage Bio Inc (PASG)

US · Healthcare · Biotechnology

$5.04+3.70%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-7.8M

EPS

$-2.44

EPS estimate

$-2.20

EPS came in at -2.44 against a street estimate of -2.20 — a miss of 10.9%.

Key statistics

Market cap

$15.3M

Forward P/E

0.0

P/B

3.55

Book value

$1.39

EPS (TTM)

$-11.03

52-week high

$20.00

52-week low

$3.29

50-day MA

$4.65

200-day MA

$7.52

Beta

1.43

Analyst view

Analysts rate Passage Bio Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $15.50.

Shareholding

Insiders

7.71%

Institutions

46.42%

Largest institutional holders

Fund	Stake
Lynx1 Capital Management, LP	20.94%
Vestal Point Capital LP	9.48%
Renaissance Technologies Corp	4.15%
Vanguard Capital Management, LLC	3.54%
Yiheng Capital LLC	2.68%
Erste Asset Management GmbH	2.65%
Ikarian Capital, LLC	2.12%
Geode Capital Management, LLC	1.29%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Passage Bio Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.